The clinical heterogeneity of Alzheimer’s disease is not reflected in the rather diffuse cortical deposition of amyloid-β. We assessed the relationship between clinical symptoms, in vivo tau pathology, amyloid distribution, and hypometabolism in variants of Alzheimer’s disease using novel multimodal PET imaging techniques. Tau pathology was primarily observed in brain regions related to clinical symptoms and overlapped with areas of hypometabolism. In contrast, amyloid-β deposition was diffusely distributed over the entire cortex. Tau PET imaging may thus serve as a valuable biomarker for the localization of neuronal injury in vivo and may help to validate atypical subtypes of Alzheimer’s disease.
JohnsonJK, HeadE, KimR, StarrA, CotmanCW (1999) Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol56, 1233–1239.
5.
OssenkoppeleR, PijnenburgYAL, PerryDC, Cohn-SheehyBI, ScheltensNME, VogelJW, KramerJH, van der VliesAE, JoieRL, RosenHJ, van der FlierWM, GrinbergLT, RozemullerAJ, HuangEJ, van BerckelBNM, MillerBL, BarkhofF, JagustWJ, ScheltensP, SeeleyWW, RabinoviciGD (2015) The behavioural/dysexecutive variant of Alzheimer’s disease: Clinical, neuroimaging and pathological features. Brain138, 2732–2749
.
6.
LehmannM, GhoshPM, MadisonC, LaforceR, Corbetta-RastelliC, WeinerMW, GreiciusMD, SeeleyWW, Gorno-TempiniML, RosenHJ, MillerBL, JagustWJ, RabinoviciGD (2013) Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer’s disease. Brain136, 844–858.
Gómez-IslaT, HollisterR, WestH, MuiS, GrowdonJH, PetersenRC, ParisiJE, HymanBT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol41, 17–24.
9.
BennettDA, SchneiderJA, WilsonRS, BieniasJL, ArnoldSE (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol61, 378–384.
JanockoNJ, BrodersenKA, Soto-OrtolazaAI, RossOA, LiesingerAM, DuaraR, Graff-RadfordNR, DicksonDW, MurrayME (2012) Neuropathologically defined subtypes of Alzheimer’s disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol124, 681–692.
12.
ChienDT, SzardeningsAK, BahriS, WalshJC, MuF, XiaC, ShankleWR, LernerAJ, SuM-Y, ElizarovA, KolbHC (2014) Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis38, 171–184.
13.
MaruyamaM, ShimadaH, SuharaT, ShinotohH, JiB, MaedaJ, ZhangM-R, TrojanowskiJQ, LeeVMY, OnoM, MasamotoK, TakanoH, SaharaN, IwataN, OkamuraN, FurumotoS, KudoY, ChangQ, SaidoTC, TakashimaA, LewisJ, JangM-K, AokiI, ItoH, HiguchiM (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron79, 1094–1108.
14.
MarquieM, NormandinMD, VanderburgCR, CostantinoI, BienEA, RycynaLG, KlunkWE, MathisCA, IkonomovicMD, DebnathML, VasdevN, DickersonBC, GompertsSN, GrowdonJH, JohnsonKA, FroschMP, HymanBT, Gomez-IslaT (2015) Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol78, 787–800.
15.
OssenkoppeleR, SchonhautDR, BakerSL, O’NeilJP, JanabiM, GhoshPM, SantosM, MillerZA, BettcherBM, Gorno-TempiniML, MillerBL, JagustWJ, RabinoviciGD (2015) Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol77, 338–342.
GaltonCJ, PattersonK, XuerebJH, HodgesJR (2000) Atypical and typical presentations of Alzheimer’s disease: A clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain123(Pt 3), 484–498.
18.
KoedamELGE, LaufferV, van der VliesAE, van der FlierWM, ScheltensP, PijnenburgYAL (2010) Early-versus late-onset Alzheimer’s disease: More than age alone. J Alzheimers Dis19, 1401–1408.
